A Risk-Based Approach for Establishing Genomic Integrity and Stability for Genetically-Engineered, Allogenic Cell Therapy Products
Time: 11:45 am
day: Day Two
Details:
• Discuss challenges of evaluating off target integration in genetically engineered products
• Discuss different approaches on off target assessment
• How to evaluate change in variants in cell therapy product throughout the manufacturing process
